慶應医学会例会

下記のとおり例会を開催いたしますので、ふるってご来聴くださいますようお願い申し上げます。

日 時 2018 年 11 月 27 日 (火) 19 : 00
場 所 新教育棟4階講堂
演 題

"Story of development of tear-free onions" that cannot be told without tears.

  Shinsuke Imai Ph.D
Basic research division Research & development headquaters House Foods Group Inc.
担 当

循環器内科学 教室
責任者:福田恵一 教授
担当者:(内線 61420)

 
  以上
日 時 2018 年 10 月 19 日 (金) 10 : 30
場 所 総合医科学研究棟 ラウンジ
演 題

Lessons from NY-ESO-1 spontaneous and vaccine-induced immunity on peripheral tolerance and future immunotherapies

  Sacha Gnjatic PhD
Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai
担 当

先端研(細胞) 教室
責任者:河上裕 教授
担当者:(内線 62708)

 
  以上
日 時 2018 年 9 月 21 日 (金) 18 : 00
場 所 臨床研究棟1Fラウンジ
演 題

Identifying new markers of placental insufficiency

  Dr. Tu'uhevaha Kaitu'u-Lino
Diagnostics Discovery and Reverse Translation, Dept of Obstetrics and Gynaecology, University of Melbourne
担 当

産婦人科学教室 教室
責任者:田中 守 教授
担当者:升田 博隆 先生 (内線 61710)

 
  以上
日 時 2018 年 9 月 6 日 (木) 17 : 30
場 所 総合医科学研究棟1階ラウンジ
演 題 Adoptive cancer immunotherapy: current topics for clinical application
  Yuki Kagoya MD, PhD
The University of Tokyo Hospital Department of Hematology and Oncology
担 当

微生物学・免疫学教室 教室
責任者:吉村 昭彦 教授
担当者:(内線 61220)

 
  以上
日 時 2018 年 8 月 22 日 (水) 17 : 00
場 所 JKiC棟1階会議室
演 題 Metabolic Adaptation in Physiology and Disease
  Shingo Kajimura Ph.D.
University of California, San Francisco, UCSF Diabetes Center Department of Cell and Tissue Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research
担 当

微生物学・免疫学教室 教室
責任者:本田 賢也 教授
担当者:新 幸二 先生 (内線 62696)

 
  以上
日 時 2018 年 8 月 9 日 (木) 19 : 00
場 所 新教育研究棟4階 講堂
演 題 Best Treatment Strategies with Statins to Maximize the CardioMetabolic Benefits
  Kwang Kon Koh MD, PhD, FACC
Gachon University
Best Treatment Strategies with Statins to Maximize the CardioMetabolic Benefits

Statins are important for preventing adverse cardiovascular events in patients with both a high risk and a low risk of vascular disease, by reducing the levels of low-density lipoprotein cholesterol. However, statins dose-dependently increase adverse effects and increase the risk of type 2 diabetes. Previously, it was hypothesized due to off-target effects, but recent studies demonstrate it was due to on-target effects. Nonetheless, the American guidelines recommend the use of high-intensity statin therapy, and extend its use to most people at risk of vascular diseases, particularly older people. On the contrary, European, Korean, and Japanese committees have expressed concerns about the potential adverse effects of using high- intensity statins in a large fraction of the population for life-long periods. Patients who have achieved low-density lipoprotein cholesterol levels below currently recommended targets may still experience cardiovascular events. This may result from residual risk. Ezetimibe, PCSK9 inhibitors, inclisiran, and ANGPTL3 antisense oligonucleotides are promising alternative non-statins drugs. Of interest, cross-talk between hypercholesterolemia and renin-angiotensin-system exists at multiple levels of insulin resistance and endothelial dysfunction. There are still unanswered questions on how to maximize the cardiometabolic benefits with statins in patients. We will discuss the results of randomized clinical trials, meta-analysis, and recent clinicopharmacogenetic studies, and propose practical guidelines to maximize the cardiometabolic benefits while reducing adverse effects and overcoming residual risk.
担 当

循環器内科 教室
責任者:福田恵一 教授
担当者:(内線 61420)

 
  以上

†先頭へ

関連病院会 クリニック情報 住所変更依頼 トップページへ戻る